Acasti Pharma (ACST)
(Delayed Data from NSDQ)
$2.73 USD
+0.16 (6.02%)
Updated Sep 17, 2024 03:40 PM ET
After-Market: $2.78 +0.05 (1.83%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMAcasti Pharma (ACST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.00 | $12.00 | $6.00 | 248.84% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Acasti Pharma comes to $9.00. The forecasts range from a low of $6.00 to a high of $12.00. The average price target represents an increase of 248.84% from the last closing price of $2.58.
Analyst Price Targets (2 )
Broker Rating
Acasti Pharma currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, two are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/16/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Strong Buy |
2/7/2024 | Craig-Hallum | Chase Knickerbocker | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 2 |
Average Target Price | $9.00 |
LT Growth Rate | NA |
Industry | Medical - Generic Drugs |
Industry Rank by ABR | 37 of 253 |
Current Quarter EPS Est: | -0.31 |
ACST FAQs
Acasti Pharma, Inc. (ACST) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 2 brokerage firms.
The average price target for Acasti Pharma, Inc. (ACST) is $9.00. The current on short-term price targets is based on 1 reports.
The forecasts for Acasti Pharma, Inc. (ACST) range from a low of $6 to a high of $12. The average price target represents a increase of $248.84 from the last closing price of $2.58.
The current UPSIDE for Acasti Pharma, Inc. (ACST) is 248.84%
Based on short-term price targets offered by two analysts, the average price target for Acasti Pharma comes to $9.00. The forecasts range from a low of $6.00 to a high of $12.00. The average price target represents an increase of 248.84% from the last closing price of $2.58.